Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...
13h
News Medical on MSNNasal spray may offer new hope for traumatic brain injury patientsA new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).
Childhood psychiatrists insist the drugs, for attention-deficit/hyperactivity disorder (ADHD) and depression, are nonaddictive and proven safe and say they are more concerned about young Americans ...
7h
Taste of Country on MSNStop Using This Nasal Wash Right Now! FDA Recall Due to Possible ‘Serious or Fatal’ SymptomsThe FDA has issued a recall for a nasal wash product after it tested positive for dangerous bacteria. Ascent Consumer ...
Nasal decongestants, often used during cold and allergy seasons, can negatively impact brain health when used long-term or in ...
Feb. 5, 2025 — New research has shown that diet could influence the risk of both depression and Alzheimer's disease (AD). Evidence suggests that depressive symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results